NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free MACK Stock Alerts $14.72 -0.02 (-0.14%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$14.68▼$14.7550-Day Range$13.06▼$15.0052-Week Range$11.45▼$15.89Volume91,728 shsAverage Volume89,858 shsMarket Capitalization$213.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merrimack Pharmaceuticals alerts: Email Address Merrimack Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy5.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 2 Articles This WeekInsider TradingAcquiring Shares$651,754 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.93 out of 5 starsMedical Sector857th out of 946 stocksPharmaceutical Preparations Industry403rd out of 437 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Merrimack Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.33% of the outstanding shares of Merrimack Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMerrimack Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Merrimack Pharmaceuticals has recently decreased by 5.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerrimack Pharmaceuticals does not currently pay a dividend.Dividend GrowthMerrimack Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MACK. Previous Next 2.9 News and Social Media Coverage News SentimentMerrimack Pharmaceuticals has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Merrimack Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for MACK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $651,754.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.87% of the stock of Merrimack Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.90% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Merrimack Pharmaceuticals is -184.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merrimack Pharmaceuticals is -184.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerrimack Pharmaceuticals has a P/B Ratio of 11.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More MACK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MACK Stock News HeadlinesMarch 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyFebruary 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)December 12, 2023 | msn.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 10, 2023 | finance.yahoo.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowNovember 10, 2023 | morningstar.comMerrimack Pharmaceuticals Inc MACKNovember 2, 2023 | finance.yahoo.comMerrimack Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | stockhouse.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 20, 2023 | theglobeandmail.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmAugust 15, 2023 | finance.yahoo.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 13, 2023 | insidermonkey.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comMerrimack Reports Second Quarter 2023 Financial ResultsJuly 18, 2023 | finanznachrichten.dePharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finance.yahoo.comPharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardSee More Headlines Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-6.24% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio43.50 Quick Ratio43.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.24Miscellaneous Outstanding Shares14,520,000Free Float10,325,000Market Cap$213.73 million OptionableOptionable Beta1.44 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 72)President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 52)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder and Scientific Advisor Comp: $4.25kGeoffrey Grande C.F.A.Senior Director of CommunicationsMs. Ellen K. Forest (Age 60)Head of Human Resources Dr. Daryl C. Drummond Ph.D. (Age 55)Head of Research Comp: $427.06kMr. Timothy R. Surgenor (Age 64)Secretary More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLVerastemNASDAQ:VSTMXOMANASDAQ:XOMAEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 8,610 shares on 3/11/2024Ownership: 4.194%Vanguard Group Inc.Bought 8,610 shares on 2/15/2024Ownership: 4.252%Barclays PLCBought 12,535 shares on 2/15/2024Ownership: 0.100%Citadel Advisors LLCBought 1,600 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 549,418 shares on 2/14/2024Ownership: 3.837%View All Insider TransactionsView All Institutional Transactions MACK Stock Analysis - Frequently Asked Questions How have MACK shares performed in 2024? Merrimack Pharmaceuticals' stock was trading at $13.41 at the beginning of the year. Since then, MACK shares have increased by 9.8% and is now trading at $14.72. View the best growth stocks for 2024 here. Are investors shorting Merrimack Pharmaceuticals? Merrimack Pharmaceuticals saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 774,100 shares, a decline of 5.9% from the February 14th total of 822,900 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is presently 8.4 days. View Merrimack Pharmaceuticals' Short Interest. When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) EPS for the quarter. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals's stock reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.25%), Vanguard Group Inc. (4.19%), ADAR1 Capital Management LLC (3.84%), Dimensional Fund Advisors LP (3.04%), Northern Trust Corp (0.82%) and Barclays PLC (0.10%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen. View institutional ownership trends. How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MACK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.